Total Payments
$181,300
2024 Payments
$3,187
Companies
18
Transactions
101
Medicare Patients
1,269
Medicare Billing
$247,802
Payment Breakdown by Category
Consulting$101,750 (56.1%)
Other$51,028 (28.1%)
Travel$23,151 (12.8%)
Food & Beverage$4,290 (2.4%)
Research$1,082 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $101,750 | 33 | 56.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $40,839 | 8 | 22.5% |
| Travel and Lodging | $23,151 | 21 | 12.8% |
| Honoraria | $10,189 | 3 | 5.6% |
| Food and Beverage | $4,290 | 34 | 2.4% |
| Unspecified | $1,082 | 2 | 0.6% |
Payments by Type
General
$180,218
99 transactions
Research
$1,082
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $36,193 | 11 | $0 (2024) |
| Takeda Pharmaceuticals International, Inc. | $28,219 | 5 | $0 (2018) |
| Seattle Genetics, Inc. | $26,535 | 26 | $0 (2019) |
| Seagen Inc. | $24,052 | 10 | $0 (2023) |
| Kyowa Kirin, Inc. | $22,436 | 20 | $0 (2023) |
| Millennium Pharmaceuticals, Inc. | $6,241 | 5 | $0 (2017) |
| Verastem, Inc. | $6,235 | 5 | $0 (2020) |
| Secura Bio, Inc. | $6,155 | 3 | $0 (2024) |
| Kyowa Kirin Services Ltd | $4,270 | 3 | $0 (2022) |
| PORTOLA PHARMACEUTICALS, LLC | $4,000 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,187 | 2 | Takeda Pharmaceuticals U.S.A., Inc. ($3,132) |
| 2023 | $31,483 | 14 | Seagen Inc. ($17,758) |
| 2022 | $8,422 | 4 | Kyowa Kirin, Inc. ($3,838) |
| 2021 | $12,539 | 7 | Secura Bio, Inc. ($6,100) |
| 2020 | $25,725 | 12 | Seagen Inc. ($6,294) |
| 2019 | $48,119 | 34 | Takeda Pharmaceuticals U.S.A., Inc. ($16,601) |
| 2018 | $28,480 | 13 | Takeda Pharmaceuticals International, Inc. ($20,472) |
| 2017 | $23,346 | 15 | Seattle Genetics, Inc. ($9,358) |
All Payment Transactions
101 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/21/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,132.15 | General |
| 07/17/2024 | Secura Bio, Inc. | COPIKTRA (Drug) | Food and Beverage | In-kind items and services | $55.27 | General |
| Category: ORAL ONCOLOGIC | ||||||
| 12/20/2023 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $937.50 | General |
| 12/20/2023 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $312.50 | General |
| 12/12/2023 | Kyowa Kirin, Inc. | Poteligeo (Drug) | Food and Beverage | In-kind items and services | $24.02 | General |
| Category: Monoclonal Antibody | ||||||
| 12/08/2023 | Kyowa Kirin, Inc. | Poteligeo (Drug) | Food and Beverage | In-kind items and services | $145.00 | General |
| Category: Monoclonal Antibody | ||||||
| 12/08/2023 | Kyowa Kirin, Inc. | Poteligeo (Drug) | Food and Beverage | In-kind items and services | $36.66 | General |
| Category: Monoclonal Antibody | ||||||
| 10/31/2023 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 09/27/2023 | Seagen Inc. | ADCETRIS (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $9,487.50 | General |
| Category: Oncology | ||||||
| 09/13/2023 | Seagen Inc. | — | Travel and Lodging | In-kind items and services | $591.85 | General |
| 09/12/2023 | Seagen Inc. | — | Travel and Lodging | In-kind items and services | $229.81 | General |
| 07/15/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ADCETRIS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,469.70 | General |
| Category: ONCOLOGY | ||||||
| 06/27/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ADCETRIS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,000.00 | General |
| Category: ONCOLOGY | ||||||
| 03/24/2023 | Seagen Inc. | ADCETRIS (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,900.00 | General |
| Category: Oncology | ||||||
| 03/09/2023 | Kyowa Kirin, Inc. | Poteligeo (Drug) | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| Category: Monoclonal Antibody | ||||||
| 02/21/2023 | Seagen Inc. | — | Travel and Lodging | In-kind items and services | $548.53 | General |
| 12/13/2022 | Kyowa Kirin, Inc. | POTELIGEO (Drug) | Honoraria | Cash or cash equivalent | $1,962.50 | General |
| Category: Monoclonal Antibody | ||||||
| 04/25/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $3,140.00 | General |
| 02/21/2022 | Kyowa Kirin Services Ltd | POTELIGEO (Drug) | Consulting Fee | Cash or cash equivalent | $1,444.29 | General |
| Category: Monoclonal Antibody | ||||||
| 02/19/2022 | Kyowa Kirin, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,875.00 | General |
| 12/08/2021 | Secura Bio, Inc. | FARYDAK (Drug), COPIKTRA | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| Category: ORAL ONCOLOGIC | ||||||
| 11/18/2021 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $937.50 | General |
| 08/12/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $1,050.00 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, CONTROLLED, PHASE 2 STUDY OF PEVONEDISTAT, VENETOCLAX, AND AZACITIDINE VERSUS VENETOCLAX PLUS AZACITIDINE IN ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA WHO ARE UNFIT FOR INTENSIVE CHEMOTHERAPY | ||||||
| 07/15/2021 | Kyowa Kirin Services Ltd | POTELIGEO (Drug) | Consulting Fee | Cash or cash equivalent | $1,440.00 | General |
| Category: MONOCLONAL ANTIBODY | ||||||
| 06/25/2021 | Acrotech Biopharma LLC | FOLOTYN (Drug), BELEODAQ | Consulting Fee | Cash or cash equivalent | $1,625.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, OPEN-LABEL, CONTROLLED, PHASE 2 STUDY OF PEVONEDISTAT, VENETOCLAX, AND AZACITIDINE VERSUS VENETOCLAX PLUS AZACITIDINE IN ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA WHO ARE UNFIT FOR INTENSIVE CHEMOTHERAPY | Takeda Pharmaceuticals U.S.A., Inc. | $1,050 | 1 |
| VS-0145-225 | Verastem, Inc. | $31.68 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 358 | 668 | $396,125 | $66,704 |
| 2022 | 6 | 339 | 674 | $390,770 | $66,337 |
| 2021 | 7 | 327 | 743 | $407,685 | $70,591 |
| 2020 | 6 | 245 | 589 | $296,275 | $44,171 |
Total Patients
1,269
Total Services
2,674
Medicare Billing
$247,802
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 116 | 252 | $183,960 | $31,395 | 17.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 24 | 115 | $59,800 | $12,283 | 20.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 91 | 135 | $73,575 | $11,052 | 15.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 23 | 23 | $24,035 | $3,751 | 15.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 42 | 45 | $16,875 | $2,362 | 14.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 11 | $11,220 | $1,712 | 15.3% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 28 | 56 | $12,320 | $1,559 | 12.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 19 | $6,840 | $1,350 | 19.7% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 11 | 12 | $7,500 | $1,240 | 16.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 100 | 267 | $197,580 | $35,597 | 18.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 102 | 155 | $84,475 | $13,297 | 15.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 26 | 84 | $44,100 | $7,828 | 17.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 23 | 23 | $24,035 | $3,936 | 16.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 52 | 56 | $21,000 | $3,068 | 14.6% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 36 | 89 | $19,580 | $2,611 | 13.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 116 | 324 | $176,580 | $28,570 | 16.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 73 | 138 | $99,360 | $18,927 | 19.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 38 | 149 | $75,245 | $14,215 | 18.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 19 | 19 | $19,855 | $3,311 | 16.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 48 | 56 | $21,000 | $3,001 | 14.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 22 | 23 | $8,165 | $1,541 | 18.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2021 | 11 | 34 | $7,480 | $1,026 | 13.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 136 | 377 | $196,040 | $26,193 | 13.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 31 | 97 | $48,015 | $9,276 | 19.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 16 | 50 | $17,250 | $3,296 | 19.1% |
About Dr. Steven Horwitz, MD
Dr. Steven Horwitz, MD is a Medical Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1811968852.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steven Horwitz, MD has received a total of $181,300 in payments from pharmaceutical and medical device companies, with $3,187 received in 2024. These payments were reported across 101 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($101,750).
As a Medicare-enrolled provider, Horwitz has provided services to 1,269 Medicare beneficiaries, totaling 2,674 services with total Medicare billing of $247,802. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location New York, NY
- Active Since 01/29/2006
- Last Updated 04/06/2015
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1811968852
Products in Payments
- ADCETRIS (Biological) $66,930
- POTELIGEO (Drug) $26,024
- ADCETRIS (Drug) $12,770
- Copiktra (Drug) $6,235
- FARYDAK (Drug) $6,100
- ANDEXXA (Biological) $4,000
- ENTYVIO (Biological) $2,800
- Poteligeo (Drug) $1,806
- FOLOTYN (Drug) $1,625
- COPIKTRA (Drug) $55.27
- Folotyn (Drug) $21.84
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in New York
Craig Thompson, Md, MD
Medical Oncology — Payments: $2.1M
Medical Oncology $2.1M
Andrew Seidman, Md, MD
Medical Oncology — Payments: $1.7M
Medical Oncology $1.7M
Dr. Joshua Richter, M.d, M.D
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Ghassan Abou-Alfa, Md, MD
Medical Oncology — Payments: $1.2M
Medical Oncology $1.2M
Edward Gelmann
Medical Oncology — Payments: $944,679
Medical Oncology $944,679
Miguel Perales, Md, MD
Medical Oncology — Payments: $759,555
Medical Oncology $759,555